Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia

Camila Bataglini 1, Isabel Ramos Mariano 2, Silvia Carla Ferreira Azevedo 3, Valder Nogueira Freire 4, Maria Raquel Marcel Natali 5, Maria Montserrat Dias Pedrosa 2, Rosane Marina Peralta 1, Anacharis B. Sá-Nakanishi 1, Lívia Bracht 1, Vilma A. Ferreira Godoy 2, Adelar Bracht 1, Jurandir Fernando Comar 1 *

1 State University of Maringá, Department of Biochemistry, Maringá, PR, Brazil
2 State University of Maringá, Department of Physiological Sciences, Maringá, PR, Brazil
3 State University of Maringá, Department of Morphological Sciences, Maringá, PR, Brazil
4 Federal University of Ceará, Department of Physics, Fortaleza, CE, Brazil

Abstract
This study investigated whether a 30-day co-treatment with 1 g/kg glutamine dipeptide (GdiP) and 1 U/kg regular (rapid acting) or 5 U/kg degludec (long acting) insulins modifies glucose homeostasis and liver metabolism of alloxan-induced type 1 diabetic (T1D) male Swiss mice undergoing insulin-induced hypoglycemia (IIH). Glycemic curves were measured in fasted mice after IIH with 1 U/kg regular insulin. One hour after IIH, the lipid profile and AST and ALT activities were assayed in the serum. Morphometric analysis was assessed in the liver sections stained with hematoxylin-eosin and glycolysis, glycogenolysis, gluconeogenesis and ureagenesis were evaluated in perfused livers. T1D mice receiving GdiP or the insulins had a smaller blood glucose drop at 60 minutes after IIH, which was not sustained during the subsequent period up to 300 minutes. The 30-day treatment of T1D mice with insulin degludec, but not with regular insulin, improved fasting glycemia, body weight gain and serum activity of AST and ALT. Treatments with insulin degludec, GdiP and insulin degludec + GdiP decreased the liver capacity in synthesizing glucose from alanine. GdiP, in combination with both insulins, was associated with increases in the serum triglycerides and, in addition, regular insulin and GdiP increased AST and ALT activities, which could be the consequence of hepatic glycogen overload. GdiP and the insulins improved the IIH, although to a small extent. Caution is recommended, however, with respect to the use of GdiP because of its increasing effects on serum triglycerides and AST plus ALT activities.

Keywords: Gluconeogenesis; Glutamine dipeptide; Insulin degludec; Insulin-induced hypoglycemia; Liver metabolism; Type I diabetes

Highlights:
• Type I diabetic mice received insulin degludec and glutamine dipeptide (GdiP) for 30 days.
• Hypoglycemia was induced in fasted diabetic mice with an injection of regular insulin.
• GdiP (1 g/kg) and insulin degludec improved the insulin-induced hypoglycemia (IIH).
• GdiP and degludec decreased the liver gluconeogenesis from alanine following IIH.
• GdiP increased the serum activity of liver transaminases and caution is recommended.

Abbreviations:
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; GdiP, glutamine dipeptide; IIH, insulin-induced diabetes; KH, Krebs–Henseleit buffer; T1D, type 1 diabetes

Introduction
In type 1 diabetes mellitus (T1D), the daily replacement of insulin is mandatory for preventing hyperglycemia, which occurs mainly as a consequence of decreased peripheral glucose uptake and upregulation of hepatic gluconeogenesis (Pra-sath et al., 2014). There are currently many types of insulin available, which differ mainly in how long they are active in the body (Silver et al., 2018). The most common type used is regular insulin, a short-acting insulin with bolus activity and effects lasting 6–8 h (American Diabetes Association, 2019). A shortcoming of regular insulin is that it can lead to alternating episodes of hypo- and hyperglycemia. Alternatively, long-
-acting or basal insulins have lower plasma concentration peaks and longer acting periods. The long-acting insulin degludec (25-h half-life) distinguishes itself for being able to maintain a more constant level of serum insulin and lower glycemic variability (Heise et al., 2012). Degludec is an insulin analogue that undergoes complexation with zinc and, after injection, forms a soluble depot in the subcutaneous tissue with a slow release of insulin into the systemic circulation (Jonassen et al., 2012).

The efficient regulation of blood glucose in T1D requires a rigid schedule of insulinization based on multiple daily doses of prandial insulins or continuous subcutaneous insulin infusion, or even the combination of basal and fast-acting insulins (American Diabetes Association, 2017). Nevertheless, most insulin therapies are associated with episodes of insulin-induced hypoglycemia (IIH) (Cryer, 2008). In healthy individuals, IIH inhibits the secretion of endogenous insulin and stimulates the secretion of counterregulatory hormones, particularly glucagon, catecholamines and cortisol, which in turn, stimulate the hepatic production of glucose and reduce its peripheral utilization, thus increasing blood glucose (Cryer, 2008). In T1D individuals, the exogenous insulin does not decrease as blood glucose decreases and, furthermore, the secretion of counterregulatory hormones is lost over time (McCrimmon and Sherwin, 2010).

L-Glutamine plays a significant role in a number of physiological processes, such as the transportation of blood ammonia and blood pH regulation (Cruzat et al., 2018). This amino acid has also been reported to have anti-inflammatory and immunomodulatory activities (Cruzat et al., 2018). In fact, L-glutamine supplementation has been reported to improve glucose homeostasis of individuals with chronic diseases, including T1D (Darmaun et al., 2019; Stehle et al., 2017).

Dietary nutrients absorbed by the enterocytes first pass through the liver before reaching the systemic circulation. This strategic position of the liver, between the gastrointestinal tract and peripheral circulation, gives it a pivotal role in the metabolic homeostasis (Sharabi et al., 2015). Glutamine is also a relevant substrate for hepatic gluconeogenesis, a crucial metabolic pathway for euglycemic maintenance after glycogen depletion during fasting and hypoglycemic episodes (Cruzat et al., 2018). In this regard, normoglycemic mice, but not T1D mice, orally receiving glutamine shortly after the IIH had higher hepatic gluconeogenesis and greater ability to recover blood glucose than mice receiving alanine or even glucose (Bataglini et al., 2017; Nunes Santiago et al., 2013). However, it is not known if long-term supplementation with glutamine attenuates episodes of IIH in T1D mice. Therefore, this study investigated whether 30-day supplementation with glutamine dipeptide (GdIP) alone or in combination with insulin degludec or regular insulin therapy modifies the glycemic homeostasis and hepatic metabolism of T1D mice during IIH. The dipeptide L-alanyl-L-glutamine, known as glutamine dipeptide, has been widely used in clinical practice as a substitution for free glutamine because, unlike the latter, the dipeptide is not consumed by intestinal cells (Raizel and Tirapegui, 2018). For 15 h were diabetized with alloxan (180 mg/kg). Four days after, fasting blood glucose was measured in blood collected by tail incision (glucometer and glycolyte Optium Xceed®, Abbott). Animals with fasting blood glucose higher than 300 mg/dl were considered T1D (Federiuk et al., 2004). All procedures were performed as recommended by the Brazilian Council for the Control of Animal Experimentation (CONCEA) and are in accordance with the European Directive 2010/63/EU. The study was approved by the Ethics Committee for Animal Use of UEM (protocol number 1334110116).

**Experimental design and treatment**

Diabetic mice were distributed into six groups (n = 7 per group): D, which received saline; DG, which received glutamine dipeptide (GdIP); DIR, which received regular insulin; DIR+G, regular insulin and GdIP; DIT, insulin degludec; and DIT+G, insulin degludec and GdIP. Seven non-diabetic mice served as controls (C). For 30 days the animals received daily 1 kg/kg GdIP (oral gavage) or saline and, for the same period, saline (s.c.) or 1 U/kg i.p. regular insulin (Humulin® R; Eli Lilly) or 5 U/kg s.c. insulin degludec (Tresiba® FlexTouch®, Novo Nordisk®). The dose of insulin degludec (5 U/kg) was based on a previous study which revealed that this dose led to stable blood glucose in mice (Bataglini et al., 2017). This dose would correspond to a human dose of 0.4 U/kg as given by the body surface area normalization method (Reagan-Shaw et al., 2007).

**Glycemic curves**

After treatment for 30 days, 15 h fasted T1D animals received regular insulin (1 U/kg) to induce IIH at 8 a.m. (time 0). Blood samples were collected from the tail at times 0, 15, 30, 60, 120, 180, 240 and 300 min to measure blood glucose. This procedure aimed to characterize the periods of lower blood glucose and blood glucose recovery. This same protocol was conducted to evaluate the response of T1D animals during IIH to the counterregulatory hormones glucagon (0.02 mg/kg), cortisol (20 mg/kg) or adrenaline (1 mg/kg). For this, the hormones were administered (s.c.) 15 min after IIH.

**Liver perfusion**

After 30-day treatment, 15 h fasted control and T1D mice received regular insulin to induce IIH and cortisol 15 min later. One hour after IIH, the non-recirculating liver perfusion was performed as previously described (Broetto-Biazon et al., 2009; Nunes Santiago et al., 2013). After an initial period of 10 min of perfusion to stabilize the preparation, samples of the effluent perfusion fluid were collected at five-minute intervals and analyzed for their content of glucose, lactate, pyruvate, ammonia and urea (Bergmeyer, 1974). During this period, liver perfusion was performed as follows: 30 min with Krebs–Henseleit buffer (KH), 30 min with KH plus glucagon (1.0 µM), 30 min with KH plus L-alanine (5.0 mM) and another 30 min with KH. L-Alanine was used as substrate because it is one of the main gluconeogenic precursors in humans and rodents and, in contrast to glutamine, it is rapidly converted into glucose and its deamination does not require previous activation by ammonium in the liver (Comar et al., 2010). Fig. 2 illustrates the perfusion protocol.

**Tissue collection and processing**

After treatment for 30 days, animals fasted for 15 h were anesthetized with Thionembutal® (30 mg/kg i.p.) and lidocaine (10 mg/kg) and blood was collected by cardiac puncture, centrifuged and serum separated to measure total cholesterol, triglycerides, and the activity of ALT and AST. Next, a vertical
laparotomy was performed and the liver removed for morphometric analysis.

For histological processing, the liver samples were fixed in 10% Bouin solution, dehydrated in ethanol gradient, cleared in xylol and embedded in paraffin blocks. Semi-serial 6 μm thick cross-sections were prepared with a rotary microtome (Leica RM2245), mounted on slides and stained with hematoxylin-eosin.

**Morphometric analyses**

Morphometric analyses were done with images of the liver parenchyma in the region near the central vein. Images were captured from an optical microscope (Olympus BX41®, Japan) with a QColor3® camera (Olympus American INC, Canada), coupled with the software Q-Capture®. Hepatocytes number and area were evaluated using the program Image-Pro Plus® 4.5 (Media Cybernetics). For quantifying the hepatocytes areas, 200 hepatocytes per animal were examined, totaling 1000 hepatocytes per group (μm²). For the number of hepatocytes, 30 images per animal were counted, totaling 150 images per group (12.592.39 μm² per group). The results were expressed as mean ± SEM.

**Statistical analysis**

The error parameters presented in graphs and tables are standard errors of the means. Statistical analysis was done by means of GraphPad Prism Software (version 5.0). The statistical significance of the data was analyzed by means of ANOVA one-way, and a Tukey post-hoc test was applied with the 5% level of significance (p < 0.05). For histological analysis, the data were first analyzed by Kolmogorov–Smirnov test for testing normality of distribution. Subsequently, the parametric data were analyzed by ANOVA one-way and Tukey’s post-hoc testing.

**Results**

**Glycemic curves and serum lipid profile**

Fig. 1A shows the results obtained with animals that received solely regular insulin to induce IIH. Fig. 1B shows other groups treated identically that received cortisol 15 min after IIH. The results obtained with glucagon and adrenaline are not shown because these agents decreased the blood glucose even more when compared to the diabetic mice (D) undergoing IIH, i.e., these hormones apparently did not elicit any counterregulatory response. Only cortisol prevented the drop in blood glucose to values below those of group D and for this reason was used in the next procedures.

In untreated diabetic mice (D), the induction of IIH diminished the blood glucose progressively, reaching values below 100 mg/dl (Fig. 1A). At 60 min, blood glucose was still relatively high, but it can already be considered a hypoglycemic situation because blood glucose reached less than 50% of the value before IIH and signs denoting the condition, particularly lethargy, were observed. In DIT and DIT+G animals, blood glucose at time 0 was even lower. The response to IIH in the DIT group was fast, i.e., a glycemic level at or slightly under 100 mg/dl was already reached after 60 min. In the GdiP treated groups (DG, DIR+G and DIT+G), the response was delayed, as blood glucose remained relatively high at 60 min and a pronounced drop occurred only later. This is particularly true for DIR+G. Animals treated with regular insulin (DIR) were also less responsive to the sudden IIH.

The simultaneous administration of cortisol produced a few changes (Fig. 1B). In the DIT group the strong response to IIH at 60 min (with blood glucose 40% lower than in group D), was almost abolished by cortisol and the overall response of DIT was made very similar to the responses of the other groups. This result suggests that, at 60 min, cortisol was effective in inducing a counterregulatory response.

Table 1 shows the body weight gain and serum levels of total cholesterol and triglycerides. The body weight gain during the 30-day treatment was 36% lower in the T1D groups and even lower (64%) in the DG group. Serum triglycerides were increased by approximately 80% in DIR+G and DIT+G mice. Serum cholesterol was practically not modified.

**Liver metabolism**

The hepatic outputs of glucose, lactate, pyruvate, urea and ammonia are shown in Fig. 2 as a function of the perfusion time. The glucose output in livers from D, DG and DIR+G was high after starting perfusion with KH alone, but with a continuous decline up to 30 min. This phenomenon mainly reflects glucose release from the glycogen stores, which are usually higher in diabetic animals (Comar et al., 2016). The declining rates of glucose and lactate at the beginning of the perfusion (0–30 min) can be best appreciated by evaluating the AUC, which correspond to the total amounts released during the initial 30 min. Fig. 3 shows the amounts of glucosyl units released as glucose, lactate and pyruvate (here assumed to be an estimate of total glycogenolysis) and those diverted into glycoysis (lactate plus pyruvate), expressed as C6 units for each condition (Castro-Ghizoni et al., 2017). Glycogenolysis was 230, 470 and 140% higher in D, DG and DIR+G, respectively (compared to the controls). Glycolysis was higher in the livers of DG (150%), but lower in the livers of DIT (40%) and DIT+G (50%).

In terms of the carbon flow derived from glycogen catabolism, still present at 30 min perfusion time, it superimposes on the carbon flow derived from alanine, a condition that makes interpretation difficult. In an attempt to minimize this problem, glucagon was introduced at 30–60 min to further deplete the glycogen stores (Fig. 2). Livers from DIR+G responded with a transient increase in glucose release, denoting a significant amount of degradable glycogen. For all other groups, glucose or lactate release continued to decrease until the final period of glucagon infusion.

The substitution of glucagon by alanine (at time 60 min) resulted in different increases in the outputs of all metabolites, which tended to stabilize during the last min of the alanine infusion. These steady-state rates were used to calculate the metabolic fluxes dependent solely on alanine transformation by subtracting the metabolic fluxes dependent on endogenous substrates. The latter was inferred from the final base line achieved during the period between 20–30 min following cessation of alanine infusion. Fig. 4A reveals that acceleration of alanine gluconeogenesis was not found irrespective of the condition. However, diminished rates of glucose production, when compared to control mice, were found in DIT and DIT+G (∼25%) and in DG (∼33%) mice. Treatment with regular insulin maintained the gluconeogenic activity close to that observed in the livers of control mice. The rates of lactate production (Fig. 4C) were high and close to normal in livers from D and DG, and low in livers from DIR, DIR+G, DIT and DIT+G, actually very low for the latter. Pyruvate production behaved similarly (Fig. 4D), the lowest rates having occurred in the livers of DIR+G, DIT and DIT+G. The lactate to pyruvate ratio, which in the liver reflects the cytosolic NADH to NAD+ ratio (Sies, 1982), presented several differences among the various groups (Fig. 4B). The highest ratio was in the livers of DIR+G.
The carbon flow represented by panels A, C and D in Fig. 4, must have its counterpart in the nitrogen flow, which is shown in panels E and F. In general, the groups that presented lower rates of glucose, lactate and pyruvate production also presented lower rates of nitrogen detoxification. This is an expected phenomenon which can be best appreciated by examining Fig. 5, in which the changes in 3C fluxes caused by alanine are represented in one panel (A) and the corresponding 1N fluxes in the other (B). In general, lower carbon fluxes corresponded to lower nitrogen fluxes as both variables presented a relatively good correlation ($r = 0.92$), with a 1N/3C mean ratio of $0.921 \pm 0.044$. The expected ratio should be close to unity and thus the value that was found is a good approximation. It is clear that livers treated with insulin degludec present the lowest rates of alanine metabolism, DIT+G being inferior to DIT. Apparently, the simultaneous GdiP treatment enhances the effect of insulin degludec treatment. Interestingly, the opposite occurs with regular insulin: in this case the simultaneous GdiP treatment tends to increase alanine metabolism.

![Fig. 1. Effects of 30-day treatment with glutamine dipeptide (GdiP; 1 g/kg), regular insulin (1 U/kg) or insulin degludec (5 U/kg) on glycemic curves of T1D mice during IIH (A) and IIH + cortisol (B). Symbols: D, saline; DG, GdiP; DIR, regular insulin; DIT, insulin degludec; DIR+G, regular insulin + GdiP; DIT+G, insulin degludec + GdiP. Values are the mean ± SEM of 5 animals. * $p \leq 0.05$ for 0 min × 0 min of D; b $p \leq 0.05$ for 60 min × 60 min of D; a $p \leq 0.05$ for 300 min × 60 min intragroup. # $p \leq 0.05$ for IIH + cortisol × IIH.

**Table 1.** Body weight gain, blood glucose and serum lipids of 15 h fasted mice after 30-day treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C</th>
<th>D</th>
<th>DG</th>
<th>DIR</th>
<th>DIR+G</th>
<th>DIT</th>
<th>DIT+G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight gain (g)</td>
<td>22 ± 1a</td>
<td>14 ± 2b</td>
<td>8 ± 1c</td>
<td>12 ± 1b</td>
<td>13 ± 1b</td>
<td>18 ± 1a</td>
<td>12 ± 1b</td>
</tr>
<tr>
<td>Fasting blood glucose (mg·dl⁻¹)</td>
<td>106 ± 2a</td>
<td>439 ± 10b</td>
<td>487 ± 13b</td>
<td>480 ± 10b</td>
<td>490 ± 15b</td>
<td>395 ± 4c</td>
<td>390 ± 4c</td>
</tr>
<tr>
<td>Triglycerides (mg·dl⁻¹)</td>
<td>45 ± 2a</td>
<td>49 ± 3a</td>
<td>49 ± 2a</td>
<td>61 ± 5a</td>
<td>90 ± 4c</td>
<td>47 ± 3a</td>
<td>80 ± 4b</td>
</tr>
<tr>
<td>Total cholesterol (mg·dl⁻¹)</td>
<td>94 ± 1.6a</td>
<td>103 ± 1a</td>
<td>102 ± 6a</td>
<td>67 ± 2b</td>
<td>107 ± 3a</td>
<td>103 ± 2a</td>
<td>72 ± 4b</td>
</tr>
</tbody>
</table>

Control (C); T1D (D), saline; DG, GdiP; DIR, regular insulin; DIT, insulin degludec; DIR+G, regular insulin + GdiP; DIT+G, insulin degludec + GdiP. Values are the mean ± SEM of 5 mice. Values with different superscript letters in the same line are different ($p < 0.05$).
Fig. 2. Time courses of glucose, lactate, pyruvate, ammonia and urea in the perfused liver of T1D mice during IIH under various conditions. Regular insulin (1 U/kg) was administered to the 15 h fasted mice (IIH induction) and cortisol (20 mg/kg), respectively, 1 h and 45 min prior to the liver perfusion procedure. Glucagon (1.0 μM) and L-alanine (5.0 mM) were infused in combination with KH buffer as shown by the horizontal bars. The abbreviations of the groups are defined in Table 1. Values are expressed as μmol per min per g of liver tissue and they are the mean ± SEM of 5 animals for each group.
Fig. 3. Glycogenolysis and glycolysis in the perfused liver of T1D mice during IIH. The values are the area under the curve (AUC) corresponding to the 0 to 30 time interval in Fig. 2. Glycolysis was taken as (pyruvate + lactate)/2 and glycogenolysis as glucose + [(lactate + pyruvate)/2]. The abbreviations of the groups are defined in Table 1. Values are the mean ± SEM (n = 5). Values with different letters in the same panel are different (p ≤ 0.05 C).

Fig. 4. Steady-state rates of metabolic fluxes derived from alanine metabolism in perfused livers of T1D mice during IIH. The steady-state rates achieved at 90 min perfusion time in the experiments shown in Fig. 2 were used to calculate the metabolic fluxes dependent solely on alanine transformation by subtracting the metabolic fluxes dependent on endogenous substrates. The abbreviations of the groups are defined in Table 1. Values are the mean ± SEM of 5 animals. Values with different letters in the same panel are different (p ≤ 0.05).
In T1D individuals, recurrent episodes of hyper- and hypoglycemia take place as a consequence of inadequate insulin therapy or poor diet. In particular, the recurrent hypoglycemia has devastating effects on the well-being of individuals. This study used alloxan-induced T1D mice subjected to 30-day supplementation with GdIP in combination with degludec or regular insulins in an attempt to contribute to a better understanding of the phenomenon. The results show that blood glucose of 15 h fasted and untreated T1D mice drops sharply 60 min after IIH and achieves values slightly above 50 mg/dl at 300 min. This similar fact has also been found in patients and rodents with type 2 diabetes and T1D (Bataglini et al., 2017; Chakera et al., 2018). The blood glucose of fasted normoglycemic mice also drops sharply 60 min after IIH but it recovers almost completely after 300 min (Nunes Santiago et al., 2013). In the present study, only a relatively poor response to hypoglycemia was observed in T1D mice receiving cortisol. Thus, this model of IIH is similar to T1D patients with very low or no response to the hypoglycemic counterregulatory system (McCrimmon and Sherwin, 2010). Untreated T1D mice additionally presented increased serum transaminases. The latter phenomenon has also been reported for T1D patients and it is related to poorer glycemic control and even liver failure (Stadler et al., 2017).

Glutamine is the most abundant endogenous glucogenic precursor, and supplementation with this amino acid should relieve the hypoglycemia episodes (Cruzat et al., 2018). In our study, glutamine was orally administered as a dipeptide (GdIP). After absorption by the enterocytes it firstly passes through the liver where it can modify the hepatic response to IIH at 60 min, a phenomenon that was not maintained at 180–300 min. In this regard, glutamine orally administered at a dose of 0.1 g/kg to normoglycemic mice after IIH has

**Liver morphometry and serum transaminases activities**

The liver weight was not different for the C, DIR and DIT groups, but it was approximately 30% higher in the D, DG, DIR+G and DIT+G groups (Table 2). The results of the morphometric analyses are also listed in Table 2. The hepatocytes areas were 10–15% higher in the D, DIR and DIR+G groups and the hepatocytes number was approximately 25% higher in the D, DG, DIR and DIT+G mice when compared to C. The increase of the number of hepatocytes was lower for DIR (+12%) and non-existent for DIR+G. The serum activities of transaminases were measured to evaluate if the morphometric modifications are related to liver damage. The AST activity was increased by 240%, 480%, 600% and 390%, respectively, for D, DG, DIR and DIR+G when compared to C. The ALT activity was also increased in the same groups and the activities of both ALT and AST were not modified in DIT and DIT+G mice.

**Discussion**

**The glycemic response to IIH after GdIP and insulin degludec treatment**

In T1D individuals, recurrent episodes of hyper- and hypoglycemia take place as a consequence of inadequate insulin therapy or poor diet. In particular, the recurrent hypoglycemia has devastating effects on the well-being of individuals. This study used alloxan-induced T1D mice subjected to 30-day supplementation with GdIP in combination with degludec or regular insulins in an attempt to contribute to a better understanding of the phenomenon. The results show that blood glucose of 15 h fasted and untreated T1D mice drops sharply 60 min after IIH and achieves values slightly above 50 mg/dl at 300 min. This similar fact has also been found in patients and rodents with type 2 diabetes and T1D (Bataglini et al., 2017; Chakera et al., 2018). The blood glucose of fasted normoglycemic mice also drops sharply 60 min after IIH but it recovers almost completely after 300 min (Nunes Santiago et al., 2013). In the present study, only a relatively poor response to hypoglycemia was observed in T1D mice receiving cortisol. Thus, this model of IIH is similar to T1D patients with very low or no response to the hypoglycemic counterregulatory system (McCrimmon and Sherwin, 2010). Untreated T1D mice additionally presented increased serum transaminases. The latter phenomenon has also been reported for T1D patients and it is related to poorer glycemic control and even liver failure (Stadler et al., 2017).

Glutamine is the most abundant endogenous glucogenic precursor, and supplementation with this amino acid should relieve the hypoglycemia episodes (Cruzat et al., 2018). In our study, glutamine was orally administered as a dipeptide (GdIP). After absorption by the enterocytes it firstly passes through the liver where it can modify the hepatic response and contribute to glycemic recovery. GdIP, at the dose of 0.4 g/kg, is most commonly used for hospital treatment of catabolic individuals. However, doses as high as 1.0 g/kg are not uncommon (Oguz et al., 2007). GdIP at the dose of 1.0 g/kg is equivalent to 0.6 g/kg of glutamine since this dipeptide (MW: 235) is composed of one molecule of glutamine (MW: 146) plus one molecule of alanine (MW: 89). The supplementation of T1D mice with GdIP did not improve fasting blood glucose or body weight gain, but it slightly attenuated the IIH at 60 min, a phenomenon that was not maintained at 180–300 min. In this regard, glutamine orally administered at a dose of 0.1 g/kg to normoglycemic mice after IIH has

**Table 2. Morphometric analyses and serum transaminases activity**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C</th>
<th>D</th>
<th>DG</th>
<th>DIR</th>
<th>DIR+G</th>
<th>DIT</th>
<th>DIT+G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver weight (g)</td>
<td>1.9 ± 0.1a</td>
<td>2.3 ± 0.1b</td>
<td>2.5 ± 0.1b</td>
<td>1.7 ± 0.1a</td>
<td>2.8 ± 0.1c</td>
<td>1.9 ± 0.1a</td>
<td>2.7 ± 0.1c</td>
</tr>
<tr>
<td>Number of hepatocytes (mm²)</td>
<td>228 ± 10a</td>
<td>282 ± 7b</td>
<td>284 ± 10b</td>
<td>256 ± 7c</td>
<td>235 ± 6a</td>
<td>297 ± 4b</td>
<td>286 ± 7b</td>
</tr>
<tr>
<td>Area of hepatocytes (μm²)</td>
<td>329 ± 8a</td>
<td>384 ± 13b</td>
<td>330 ± 8a</td>
<td>370 ± 10b</td>
<td>364 ± 7b</td>
<td>328 ± 14a</td>
<td>332 ± 7a</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>53 ± 4a</td>
<td>179 ± 7b</td>
<td>308 ± 13a</td>
<td>381 ± 10d</td>
<td>261 ± 4e</td>
<td>34 ± 6a</td>
<td>35 ± 2a</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>12 ± 1a</td>
<td>128 ± 3b</td>
<td>178 ± 9c</td>
<td>173 ± 5c</td>
<td>153 ± 7c</td>
<td>24 ± 1a</td>
<td>12 ± 1a</td>
</tr>
</tbody>
</table>

The abbreviations of the groups are defined in Table 1. Data represent the mean ± standard error (n = 5). Values with different superscript letters in the same line are different (p < 0.05).
been associated with a greater ability to recover blood glucose (Nunes Santiago et al., 2013). However, the hepatic gluconeogenesis from glutamine or alanine of untreated mice during IIH is higher than in normoglycemic mice only when the liver is perfused with saturating levels of these substrates (12–16 mM) (Nunes Santiago et al., 2013). In addition, T1D mice receiving glutamine (1 g/kg) shortly after IIH had a smaller fall of blood glucose at 60 min, which was not maintained at 180–300 min and only occurred in association with cortisol (Bataglini et al., 2017).

T1D mice treated with insulin degludec provided better results than regular insulin in relation to parameters that were not modified by IIH, such as, for example, fasting blood glucose level and body weight gain. However, T1D mice treated with degludec had a more severe hypoglycemia at 60 min after IIH. This event was partly minimized by cortisol. In other words, mice treated with degludec may have preserved some response to the cortisol-linked counterregulatory system. Another difference was the serum transaminases. While insulin degludec reduced the activity of AST and ALT in T1D mice, regular insulin markedly increased the activity of both enzymes. In this regard, a transient elevation of serum transaminases after starting insulin therapy has been reported for T1D patients with ketosis or ketoacidosis related to poorly controlled diabetes and might imply severe dysfunction of glucose metabolism in the liver (Takaike et al., 2004, 2008). In fact, hyperglycemia and sustained levels of exogenous insulin are associated with hepatic glycogen overload and consequent liver damage in T1D (Giordano et al., 2014; Rajas et al., 2013). Elevated serum AST and ALT were also found in T1D rats 30-day treated with glutamine (0.4 g/kg) alone or in combination with regular insulin (Azevedo, 2019).

**Alanine metabolism in mice livers after GdiP and insulin degludec treatment**

The results on alanine metabolism obtained with the perfused liver must be regarded in terms of medium- and long-term regulation under the conditions of the various treatments, i.e., modifications in the expression of enzymes and other molecules over time, which are preserved in the isolated organ. On the other hand, short-term regulation, as given by hormones such as glucagon and catecholamines, for example, reversibly acting allosteric effectors and in vivo substrate concentrations are absent because they are lost when the liver is removed. Consequently, the experiments are actually revealing the response of the enzymatic system as established just before the organ isolation. Substrate concentrations, for example, are different in vivo and in the perfused liver. The alanine concentration in vivo is much lower than the concentration used in the liver perfusion experiments (5 mM). Even so, it is appropriate to analyze the compatibility between the in vivo and in vitro observations because the latter are likely to reflect medium- and long-term regulations.

Livers from D, DG and DIR+G mice present intense glycogenolysis just after starting perfusion. Intense glycogenolysis is the only explanation for the high rates of glucose output when perfusion is done in the absence of exogenous substrates because the contribution of endogenous substrates is minimal – as shown by several studies, which also reveal high levels of hepatic glycogen in T1D animals not injected with insulin (Comar et al., 2016; Gannon and Nuttall, 1997). Furthermore, high rates of glucose release when under substrate-free perfusion were absent in livers of DIR, a probable consequence of lower levels of glycogen induced by the insulin treatment. An even smaller output of glycogenolytic products tended to occur in livers from DIT and DIT+G. Singularly, the latter two groups are precisely those that present the lowest blood glucose after the 15 h fasting period, suggesting that a diminished glycogenolysis might have contributed to this. It is not the only cause, however, because livers from DIT and DIT+G also presented the lowest gluconeogenesis from alanine. Livers from DIR and DIR+G, on the other hand, which also presented high glycemic levels after a 15 h fast without accelerated glycogenolysis, had normal gluconeogenesis, suggesting that the latter was an important component for maintaining high glycemic levels.

The diminished gluconeogenesis of the DG mice group and of the DIT and DIT+G groups may have different causes if one looks at the rates of lactate production, which were high in the DG group and low in the DIT and DIT+G groups – actually very low for the latter. DIT and DIT+G presented lower rates of alanine transformation leading to lower rates of carbon and nitrogen fluxes. In contrast, the rate of alanine transformation in DG was high in terms of carbon and nitrogen fluxes, but a part of the amino acid was deviated into lactate production. These observations suggest that GdiP alone might have induced some limitation along the gluconeogenic pathway in spite of an efficient alanine transformation, whereas insulin degludec blocks alanine uptake in its initial steps. This conclusion must be regarded as highly preliminary and must be evidently confirmed by further experimentation.

**Liver morphometry after GdiP and insulin degludec treatment**

The supplementation of T1D mice with GdiP was followed by a significant increase in the serum transaminases activity and organ weight, phenomena that may be associated with liver glycogen overload. Glutamine is not only an effective amino acid for enhancing glycogen formation, but it has also been associated with the stimulation of glycogen synthetase (Cruzat et al., 2018; Stumvoll et al., 1999). In addition, T1D mice receiving GdiP in combination with both insulins presented higher levels of serum triglycerides. One possible justification is the increased availability of substrates is a consequence of GdiP supplementation associated with sustained levels of exogenous insulin.

With respect to the morphometric analyses, the increased liver weight was always associated with increased hepatocytes number and/or area. Glutamine is known to cause hepatocyte swelling that should increase the hepatocyte area. The latter was not found, but all groups that received GdiP presented higher liver weights, what might be due to higher glycogen content. In fact, the liver enlargement that occurs in B6C3F1 mice upon short-term exposure to dichloroacetic acid has been associated with liver hypertrophy due to increased glycogen content (Carter et al., 1995). In turn, T1D mice treated with GdiP + degludec had higher liver weight, but both glycogenolysis (and probably glycogen content) and serum transaminases were not increased. In any case, this study shows for the first time that the number and area of hepatocytes are increased in alloxan-induced T1D mice.

**Conclusions**

The 30-day treatment of T1D mice with insulin degludec, but not with regular insulin, improved fasting blood glucose, body weight gain and serum activity of AST and ALT. GdiP and both insulins at least minimally improved the IHH of T1D mice. Treatments with insulin degludec, GdiP and degludec + GdiP
decreased the capacity of the liver to synthesize glycogen from alanine. These hypothetically beneficial effects must be regarded in conjunction with potentially adverse events. GdIP, in combination with both insulins, was associated with increases in the serum triglycerides, and regular insulin and GdIP increased the serum activity of AST and ALT, which seems to be a consequence of hepatic glycogen overload. Thus, the recommendation of long-term supplementation with 1 g/kg GdIP for T1D individuals should be viewed with caution, especially if associated with regular insulin.

**Ethical aspects and conflict of interests**

The authors have no conflicts of interest to declare. All of the authors have approved the final manuscript.

**Role of the funding source**

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) had no involvement in the study design, the collection, analysis and interpretation of data, the writing of the report, nor the decision to submit the article for publication.

**Acknowledgements**

The authors wish to thank CAPES and CNPq for the financial support.

**References**


Azevedo SCF (2019). Efeitos da associação entre insulinoferia e suplementação oral com l-glutamina sobre a morfofisiologia hepática de ratos wistar diabéticos tipo 1. Ph.D. Thesis (Postgraduate Program in Biological Sciences), State University of Maringá, PR, Brazil. [online] [cit. 2020-11-28]. Available at: http://repositorio.uem.br:8080/jspui/handle/1/5700


